- Home
- GTX vs AGIO Comparison
GTX vs AGIO Comparison
Compare GTX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTX
- AGIO
- Stock Information
- Founded
- GTX 2018
- AGIO 2007
- Country
- GTX Switzerland
- AGIO United States
- Employees
- GTX N/A
- AGIO N/A
- Industry
- GTX Auto Parts:O.E.M.
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- GTX Consumer Discretionary
- AGIO Health Care
- Exchange
- GTX Nasdaq
- AGIO Nasdaq
- Market Cap
- GTX 1.8B
- AGIO 1.4B
- IPO Year
- GTX N/A
- AGIO 2013
- Fundamental
- Price
- GTX $8.94
- AGIO $27.14
- Analyst Decision
- GTX Strong Buy
- AGIO Buy
- Analyst Count
- GTX 1
- AGIO 8
- Target Price
- GTX $12.00
- AGIO $56.57
- AVG Volume (30 Days)
- GTX 1.9M
- AGIO 749.3K
- Earning Date
- GTX 05-01-2025
- AGIO 05-01-2025
- Dividend Yield
- GTX 0.68%
- AGIO N/A
- EPS Growth
- GTX N/A
- AGIO N/A
- EPS
- GTX 1.26
- AGIO 11.64
- Revenue
- GTX $3,475,000,000.00
- AGIO $36,498,000.00
- Revenue This Year
- GTX N/A
- AGIO $41.13
- Revenue Next Year
- GTX $7.85
- AGIO $234.96
- P/E Ratio
- GTX $7.02
- AGIO $2.39
- Revenue Growth
- GTX N/A
- AGIO 36.07
- 52 Week Low
- GTX $7.02
- AGIO $23.42
- 52 Week High
- GTX $10.39
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- GTX 54.69
- AGIO 42.53
- Support Level
- GTX $7.84
- AGIO $23.42
- Resistance Level
- GTX $9.22
- AGIO $28.24
- Average True Range (ATR)
- GTX 0.47
- AGIO 1.89
- MACD
- GTX 0.13
- AGIO 0.15
- Stochastic Oscillator
- GTX 87.50
- AGIO 50.82
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.